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ABSTRACT
A multitude of pharmacokinetics studies have been
published. However, due to the lack of an open
database, pharmacokinetics data, as well as the
corresponding meta-information, have been difficult
to access. We present PK-DB (https://pk-db.com),
an open database for pharmacokinetics information
from clinical trials. PK-DB provides curated informa-
tion on (i) characteristics of studied patient cohorts
and subjects (e.g. age, bodyweight, smoking status,
genetic variants); (ii) applied interventions (e.g. dos-
ing, substance, route of application); (iii) pharma-
cokinetic parameters (e.g. clearance, half-life, area
under the curve) and (iv) measured pharmacokinetic
time-courses. Key features are the representation of
experimental errors, the normalization of measure-
ment units, annotation of information to biological
ontologies, calculation of pharmacokinetic parame-
ters from concentration-time profiles, a workflow for
collaborative data curation, strong validation rules
on the data, computational access via a REST API
as well as human access via a web interface. PK-
DB enables meta-analysis based on data from multi-
ple studies and data integration with computational
models. A special focus lies on meta-data relevant for
individualized and stratified computational modeling
with methods like physiologically based pharmacoki-
netic (PBPK), pharmacokinetic/pharmacodynamic
(PK/PD), or population pharmacokinetic (pop PK)
modeling.
INTRODUCTION
The pharmacokinetics (PK) of drugs and medication,
i.e. how the body after administration affects substances via
absorption, distribution, metabolization, and elimination,
are of great interest for medical research and drug devel-
opment. The main measures in the field are concentration-
time profiles and derived PK parameters from these time-
courses like half-lifes or clearance rates. These measures
strongly depend on the dosage and individual character-
istics of the subject or group under investigation. Factors
like age, weight, sex, smoking behavior, genetic variants or
disease drive the large inter-individual variability in PK (1)
making such meta-data indispensable for research in phar-
macokinetics. The study of variability in drug exposure due
to these covariates is an important field of research with a
long history, generally referred to as population pharma-
cokinetics (2). Modern approaches go beyond classical pop-
ulation information by accounting for additional factors,
for example, for genetic variants (3). This meta-information
on subjects in combination with the main measures are the
basis for individualized and stratified approaches in drug
treatment which will potentially pave the road towards both
precision dosing and precision medicine.
A multitude of PK studies have been published but de-
spite the wealth of literature almost none of the data is ac-
cessible in a machine-readable format and certainly not with
FAIR (findable, accessible, interoperable and reproducible)
principles (4) in mind. The lack of transparency and repro-
ducibility (5) in the field is ubiquitous. Currently the only
way to retrieve this treasure is by digitizing and curating the
pharmacokinetics information from publications. Despite
the central role of PK in the medical and pharma field, no
open freely accessible database of pharmacokinetics infor-
mation exists so far. In addition, heterogeneity in the report-
ing of clinical study designs, pharmacokinetic measures, in-
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Figure 1. PK-DB overview. Schematic overview of the curation process
and interaction with the PK-DB database. Data is either extracted from
literature (digitization of figures and tables) or data sets are directly im-
ported (from collaboration partners). Figure panels, data sets, meta-data
and study information on subjects, interventions and dosing is curated. All
data files and the study information are uploaded via REST endpoints.
The curated data is checked against validation rules, data is normalized
(e.g. units), and pharmacokinetic parameters are calculated. The uploaded
study information can either be programmatically accessed via the REST
API or via the web frontend.
dividual, and population-related meta-information further
complicates data reuse and integration. Many studies only
report a small fraction of the underlying data, e.g. individ-
ual data or prominent PK parameters are missing in most
studies and even time-courses averaged over subjects within
a group are only present in a subset of data.
For computational modeling, meta-analysis and most
methods in machine learning a standardized and machine-
readable representation of data is of major importance. PK
data could be utilized in many different ways (6–8) if such
a representation and corresponding database would exist.
One of the various applications is pharmacokinetic model-
ing which provides a unique opportunity to integrate PK
data and parameters from multiple clinical trials into a sin-
gle predictive model.
These models can integrate PK-DB data on differences in
the study protocol, the dosing, as well as individual, group
and population characteristics and be parameterized and
validated with the available time courses and pharmacoki-
netic parameters.
DESCRIPTION AND RESULTS
PK-DB (https://pk-db.com) is an open web-accessible
database storing comprehensive information on pharma-
cokinetics studies consisting of PK data, PK parameters,
and associated meta-information (see Figure 1 for a general
overview).
Database statistics
PK-DB provides curated information on (i) characteris-
tics of studied patient cohorts and subjects (e.g. age, body-
weight, smoking status, genetic variants); (ii) applied inter-
ventions (e.g. dosing, substance, route of application); (iii)
concentration-time curves and (iv) parameters measured
in PK studies (e.g. clearance, half-life and area under the
curve). The focus so far of data curation has been on sub-
stances applied in dynamical liver function tests, benzodi-
azepines, statins, and studies of glucose metabolism.
PK-DB-v0.9.3 (9) consists of 512 studies containing
1457 groups, 6308 individuals, 1408 interventions, 73 017
outputs, 3148 time-courses and 37 scatters related to ac-
etaminophen, caffeine, codeine, diazepam, glucose, mida-
zolam, morphine, oxazepam, simvastatin or torasemide (see
Figure 2, Supplementary Material 1 and Supplementary
Material 2).
Design principles
Important features of PK-DB are the representation of ex-
perimental errors, the normalization of measurement units,
annotation of information to biological ontologies, calcu-
lation of pharmacokinetic parameters from concentration-
time profiles, a workflow for collaborative data curation,
strong validation rules on the data, computational access
via a REST API as well as human access via a web inter-
face. Key principles in the design of PK-DB were:
Accessibility of data for computational modeling and data
science. All data is available via REST endpoints as well as
the web frontend allowing for simple integration of PK-DB
data into existing workflows, e.g. for the building of com-
putational models. The REST web service allows querying
and retrieving all information from PK-DB in an automatic
fashion. The major advantage of the REST API (https:
//pk-db.com/api/v1/swagger/) as a central access point is
that it can be accessed programmatically independent of
the programming language. In the following, we present
various use cases to demonstrate the usefulness of this ap-
proach, e.g. creating an overview of the database content
using R and circos (Figure 2), and meta-analyses of multi-
ple studies using Python (Figure 4). The use of PK-DB data
is facilitated by annotation of biological and medical con-
cepts to respective ontologies. This enables the integration
with additional data sets or computational models based
on the semantic information, e.g., substances are annotated
to ChEBI (10), and diseases to ncit, hp, doid and mondo
(11–14). A special focus lies on meta-data for individualized
and stratified computational modeling of pharmacokinetics
with methods like physiologically based pharmacokinetic
(PBPK), pharmacokinetic/pharmacodynamic (PK/PD) or
population pharmacokinetic (pop PK) modeling.
Extensibility and generalizability. The PK-DB data model
is not limited to a specific problem domain but allows sim-
ple extensions to other fields and experimental data sets,
within the overall area of pharmacokinetics. Examples are
extensible types for the group or individual characteristics
currently represented in the database. Additional types can
easily be added to cover the important information for a
given problem domain.
Unit and data normalization. A key challenge in using
data for computational modeling and data science are non-
standardized units coming from different data sets. It re-
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Figure 2. PK-DB content. (A) Studies. Overview of the study content in PK-DB. PK-DB-v0.9.3 (9) 512 studies containing 1457 groups, 6308 individuals,
1408 interventions, 73017 outputs, 3148 time-courses and 37 scatters related to acetaminophen, caffeine, codeine, diazepam, glucose, midazolam, morphine,
oxazepam, simvastatin or torasemide. The circular plot is structured in stripes and rings, with each stripe representing a single study. In each ring, the counts
of different data types are depicted. Dot size corresponds to the number of entries. The rings give an overview of the following information (1) name of the
study; (2) number of outputs (PK parameters and other measurements). Red dots represent reported data, blue dots data calculated from time-courses; (3)
number of time-courses; (4) number of participants. Purple dots represent participants with individual data, green dots represent participants which are
reported as a group; (5) the number of interventions applied to the participants in the study. (B) Substances Overview of the substance content in PK-DB.
Substances with very few entries (<2 studies) are excluded from the plot. The circular plot is structured in stripes and rings, with each stripe representing
a different substance. Substances were clustered in five substance classes (caffeine, glucose, codeine, and paracetamol) by agglomerative clustering of the
pair co-occurrence of substances within studies. Classes are labeled according to the most frequent substance within the class. Each co-occurrence of
two substances is visualized by a connecting ribbon between the substances in the center. The rings describe the following information for the respective
substance (1) name of the substance; (2) number of outputs (PK parameters and other measurements). Red dots represent reported data and blue dots
represent data calculated from reported concentration-time profiles. (3) the number of time-courses; (4) number of applied interventions; (5) number of
studies in which the substance occurred. For complete figures see Supplementary Material 1 and Supplementary Material 2.
the literature and error-prone conversion of units and cor-
responding data. PK-DB provides a solution to this issue.
During upload the data is harmonized, e.g. data is con-
verted between molar units and mass, using the molecular
weight of the respective substances based on its ChEBI in-
formation (10). In addition, for all information stored the
allowed units are defined (actual units must be convertible
to these units).
Representation of time-course data. The main measures in
pharmacokinetics studies are concentration-time curves of
the administered substance and its metabolites. These time-
courses are crucial for kinetic modeling, e.g. using PBPK
or PK/PD models. Consequently, a central focus was on
storing and analyzing such data efficiently.
Calculation of pharmacokinetic parameters. PK-DB cal-
culates important PK parameters such as half-life, clear-
ance or volume of distribution from the time-concentration
profiles during data upload based on non-compartmental
methods (15). Parameters are calculated based on linear re-
gression of the logarithmic concentration values in the ex-
ponential decay phase (see example in Figure 3 and Table 1).
Non-compartmental methods were chosen for comparison
of calculated values with reported PK parameters in the
literature, mainly calculated based on non-compartmental
methods.
Data quality. Strong validation (e.g. of categoricals), min-
imum relevant information, instance cross-referencing and
correct unit-dimensions ensure high quality of the curated
data. Non-obvious curation mistakes (or respective errors
in the reporting of the data) can be addressed by outlier
identification in subsequent meta-analyses.
Access rights. PK-DB allows to keep studies privately or
only share with certain collaborators. This allows sharing
the study during the curation process only with trusted peo-
ple with a simple option to make the study public. Some
information is only accessible by a limited group of users
due to copyright issues, e.g. for manually curated studies
from the literature the underlying publication can only be
made accessible if it is Open Access. A subset of studies is
currently private because the underlying raw data from the
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Figure 3. Calculation of pharmacokinetics data from time-courses.
Concentration–time courses have been digitized from figures in the liter-
ature. This example shows morphine plasma time-courses after the ap-
plication of codeine to three subgroups with different genotypes (16) (see
https://pk-db.com/data/PKDB00111). PK parameters are calculated from
reported concentration-time profiles using non-compartmental methods,
e.g. the half-life (thalf) or elimination rate (kel) of morphine. The exponen-
tial decay is used for the fitting of PK parameters (see inlet). Calculated
and reported PK parameters for this example are listed in Table 1. Due to
the unavailability of individual participant data in most pharmacokinetics
studies, parameters have to be determined on the mean time–concentration
curves (averaged over subjects in a given group). Data is mean ± standard
error (SE).
Technology
The PK-DB backend is implemented in Python using
the Django framework with Postgres as the underlying
database system. For fast, full-text search most data is in-
dexed with Elasticsearch. The provided REST API uses
the Django-rest-framework with endpoints accessible from
https://pk-db.com/api/. The web frontend (https://pk-db.
com) is implemented in JavaScript based on the Vue.js
framework interacting with the backend via the REST
API. The complete PK-DB stack is distributed as docker-
containers. PK-DB is licensed under GNU Lesser General
Public License version 3 (LGPL-3.0) with source code avail-
able from https://github.com/matthiaskoenig/pkdb.
Curation workflow
PK-DB provides a collaborative curation interface which
simplifies the upload and update of curated study infor-
mation. A central component is to track all files and cu-
ration changes via Git version control. On changes, the files
can automatically be uploaded and validated against a de-
velopment server which provides direct feedback on miss-
ing information or curation errors (e.g. units of concentra-
tion measurements must be convertible to [g/l] or [mol/l]).
A multitude of constraints have been defined as validation
rules on the uploaded data instead of having the data model
layer too restrictive. These validation rules are constantly
updated based on curator feedback. Allowed choices in the
data model are based on an internal ontology, which allows
to update encodable information without the need to up-
date the database backend.
The typical workflow for extracting data from the litera-
ture is depicted in Figure 1. At the beginning of the cura-
tion process, a body of literature is selected based on litera-
ture research for a given problem domain. Subsequently, the
relevant (meta-)information is manually extracted from the
literature and encoded in a standardized JSON format. Ex-
tracted data like concentration-time courses or PK param-
eters are stored as tabular data in spreadsheets. After finish-
ing the initial curation process, a second curator is checking
the data.
Curation is an iterative process involving multiple cu-
rators over time. Tracking changes to the curated data is
therefore crucial. Instead of implementing such history and
change tracking on database level with substantial over-
head, we utilize the full set of Git features out of the box
to track changes to our files. All curators work hereby on a
shared Git repository. Private data can be tracked in sepa-
rate private Git repositories.
Calculation of pharmacokinetic parameters
An important part of PK-DB is the automatic calculation
of PK parameters from the reported concentration-time
curves based on non-compartmental methods (15). Figure 3
and Table 1 illustrate the automatic calculation of PK pa-
rameters from concentration-time profiles for an example
study. The authors were hereby interested in the influence of
specific genetic alleles on the pharmacokinetics of codeine
(16). In the study, information was limited to the averaged
measures with variation (standard error within group), but
no individual subject data was reported.
Calculated parameters are the area under the curve
(AUCend), the area under the curve extrapolated to infin-
ity (AUC∞), the concentration maximum (Cmax), the time
at concentration maximum (tmax), the half-life (thalf), the
elimination rate (kel), the clearance (Clearance) and the vol-
ume of distribution (Vd). The calculated values are in good
agreement with the reported values (all lie within the re-
ported standard deviations).
Mathematically correct, first the PK parameters should
be calculated for each subject individually and subsequently
be averaged. Unfortunately, this is not possible if only av-
eraged data is reported. Consequently, as approximation
PK parameters are calculated on the averaged time-courses.
Due to the often very large inter-individual differences in
pharmacokinetics the calculated values on average data can
be notable different between reported and calculated pa-
rameters (Table 1, e.g. thalf). Even more fundamentally, the
description of the data as averages with variations has inher-
ent problems by assuming homogeneity of the data which
often is not the case (17). Consequently, we strongly encour-
age the publication of individual subject data in PK studies.
A further limitation of PK studies is that often only a sub-
set of pharmacokinetics information is reported. In the ex-
ample displayed in Table 1 (16), the volume of distribution
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Figure 4. Meta-analysis of caffeine clearance depending on caffeine dose. Caffeine clearance is stratified based on reported smoking and oral contraceptive
(OC) use. UNKNOWN (grey) data corresponds to unreported smoking and OC, CONTROL (green) are non-smokers not taking OC, SMOKING (blue)
are smokers not taking OC, OC (dark orange) are non-smokers taking OC, and OC-SMOKING (light orange) are smokers taking oral contraceptives. For
the stratification groups the number of individuals (I), number of groups (G) and number of total participants (TP) is provided in the legend. Individual
and group data is depicted, with group size encoded as dot size. Data points from groups are labeled by the study identifier. Reported PK parameters
are depicted as circles, PK parameters calculated from concentration-time profiles as squares, and PK parameters inferred from PK data and reported
bodyweights of the participants as triangles (to convert to dose per bodyweight). Typically, dosing is reported in mass units and clearance in a volume per
time. Sometimes both values are reported in bodyweight units. Here, all available data is harmonized. Suspicious data from four studies (18–21), very likely
from a single clinical trial, was excluded.
Meta-analysis of caffeine
PK-DB allowed us for the first time to undertake an exten-
sive and systematic analysis of the effect of lifestyle factors
like smoking and oral contraceptive use on the clearance
of caffeine combining data from multiple studies. For this
use case, we integrated data from 44 studies, based on pro-
grammatic interaction with PK-DB via the REST API. By
curating information about the respective patient character-
istics (lifestyle factors), the actual interventions performed
in the studies (dosing and route), and important informa-
tion like the errors on the reported data we could gain a
unique view on the strong and consistent effect of smoking
and oral contraceptive use on the clearance of caffeine. The
large variability between studies and individuals could be
markedly reduced by accounting for lifestyle information.
Importantly, the meta-analysis allowed us to directly im-
prove the curation status of many studies by easily detect-
ing visible outliers in the data which could in most cases
directly be backtracked to curation errors or incorrectly re-
ported data (e.g. incorrect units) which were subsequently
corrected in the database.
A positive aspect is that most of the reported studies are
consistent. For instance with caffeine, most of the data was
in line with each other with a single exception being Stille
et al. (18). Here, a systematic bias in the data could be ob-
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Table 1. Calculation of pharmacokinetic parameters. Comparison of PK
parameters for morphine reported in a representative study of codeine ap-
plication (16) (see https://pk-db.com/data/PKDB00111). PK parameters
were calculated from mean concentration-time profiles (see Figure 3). Only
data for the groups, no individual data was reported in the study
Parameter Genotype Reported PK-DB Difference (%)
(unit) xr ± SD xc xr−xcxr
AUCend *1/*1 6.63 ± 2.07 6.24 5.88
(ng/ml · h) *1/*10 3.77 ± 1.93 3.80 − 0.80
*10/*10 2.65 ± 1.95 2.59 2.26
AUC∞ *1/*1 8.52 ± 4.10 6.40 24.88
(ng/ml · h) *1/*10 5.05 ± 3.30 3.97 21.39
*10/*10 3.26 ± 2.43 2.68 17.79
Cmax *1/*1 2.06 ± 0.89 1.64 20.39
(ng/ml) *1/*10 0.96 ± 0.42 0.73 23.96
*10/*10 0.68 ± 0.50 0.59 13.24
thalf *1/*1 9.40 ± 11.70 4.15 55.85
(h) *1/*10 11.50 ± 11.10 4.76 58.61
*10/*10 6.84 ± 5.46 4.66 31.87
tmax *1/*1 0.64 ± 0.28 0.50 21.88
(h) *1/*10 0.86 ± 0.52 0.50 41.86
*10/*10 0.86 ± 0.52 1.00 − 16.28
kel *1/*1 – 0.17 –
(1/h) *1/*10 – 0.15 –
*10/*10 – 0.15 –
Reported PK parameters are presented as mean ± standard deviation (SD)
Unreported values displayed as (–)
AUC – area under the curve; Cmax – maximum concentration; thalf – half-
life; tmax – time of maximum concentration; kel – elimination rate.
the same data set was published multiple times, overall in
four publications all showing the same bias (18–21).
Data quality and validation
The integration of data from multiple studies and subse-
quent meta-analyses is a valuable procedure to identify cu-
ration errors which cannot be caught by validation rules
alone. The combination of both, the validation rules and
the meta-analyses helped to identify errors also in the re-
porting. In the following, we will give some examples of
suspicious reported data detected by meta-analysis: Wang
et al. (22) reported incorrect units; Seng et al. (23) calculated
volumes per bodyweight incorrectly; In the publication of
Carbo et al. (24) participant number 4 has a suspiciously
high half-life and participant number 3 a suspiciously high
clearance rate. It is unclear if this is a reporting error; In the
publication of Beach et al. (25) nine smokers and two non-
smokers have suspiciously very high clearance rates, again
unclear if this is a reporting error. In the publication of Wu
et al. (16) the concentration-time profiles and concentration
maxima were reported with incorrect units.
Data validation and data integration via PK-DB allowed
us to identify and correct these issues.
CONCLUSION AND DISCUSSION
PK-DB is the first open database for pharmacokinetics data
and corresponding meta-information. We provide an im-
portant resource which allows storing pharmacokinetics in-
formation in a FAIR (findable, accessible, interoperable and
reproducible) manner (4).
PK-DB is supported by the Federal Ministry of Ed-
ucation and Research (BMBF, Germany) within the re-
search network Systems Medicine of the Liver (LiSyM)
until 2021. PK-DB is a central part of the DFG funded
project QuaLiPerf (Quantifying Liver Perfusion–Function
Relationship in Complex Resection––A Systems Medicine
Approach) with maintenance guaranteed until end of 2025.
We demonstrate the value of PK-DB via a stratified meta-
analysis of pharmacokinetics studies for caffeine curated
from literature which allows us to integrate and harmonize
pharmacokinetics information from a wide range of stud-
ies and sources. By performing the curation for commonly
applied drugs (codeine and paracetamol), for a substance
used in liver function tests (caffeine), as well as for glucose
we could demonstrate the applicability of PK-DB to a wide
range of substances and gain insights into how well data is
reported in the various fields.
PK-DB has many unique features compared to existing
databases for pharmacokinetics information, such as the
database for pharmacokinetics properties (26) or the re-
cent pharmacokinetic database time-series data and param-
eters for 144 environmental chemicals (27). PK-DB allows
to handles experimental errors, the normalization of mea-
surement units, annotation of information to biological on-
tologies, calculation of pharmacokinetic parameters from
concentration-time profiles, comes with a workflow for col-
laborative data curation, has strong validation rules on the
data, and provides computational access via a REST API
as well as human access via a web interface.
The reporting of data in the field of pharmacokinetics
is very poor despite the main point of the publications be-
ing the reporting of the data. Without guidelines on mini-
mal information for studies, it is very difficult to compare
studies or integrate data from different sources. Incomplete
and poor reporting of data in the field of pharmacokinet-
ics has also been reported by others (28,29). As our analy-
sis shows, even basic information, crucial for the interpre-
tation and analyses of PK studies, are not reported in many
publications. It is impossible to integrate and reuse such
data. For instance, in the case of codeine, often not even the
given dose can be retrieved from the publication because it
is not clearly reported which substance was administered
(codeine-sulfate, codeine-phosphate or codeine). Other ex-
amples are unreported bodyweights, so that conversions to
doses per bodyweight are not possible.
Based on our work we have a set of important sugges-
tions when publishing clinical studies in the field of pharma-
cokinetics: (i) Publish the actual data in a machine-readable
format (e.g. a data table in the supplement); (ii) Publish
the actual concentration-time curves, not only derived pa-
rameters; (iii) Provide data for individual subjects which
is much more informative and allows to calculate all data
for individuals and for groups; (iv) Provide at minimum
information on (individual) patient characteristics which
includes basic anthropometric information like age, body-
weight, sex, height, and the subset of important lifestyle fac-
tors known to alter pharmacokinetics (e.g. co-medication,
oral contraceptive use, smoking status, alcohol consump-
tion or for instance for CYP1A2 substrates like caffeine:
methylxanthine consumption/abstinence); (v) Clearly de-
scribe the study protocol: Which substance was given in
which dose, in which route (oral, intravenous), and in what
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Prospective plans for PK-DB are to increase the scope
by manual curation and semi-automatic approaches. Fur-
thermore, workflows for the deposition of pharmacokinet-
ics data upon publication will be established.
We envision that PK-DB will encourage better reporting
of pharmacokinetics studies by providing means for data
representation and integration and will improve reusability
of pharmacokinetics information by providing PK data in a
central database, and will facilitate data integration between
studies and with computational models.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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3. Lötsch,J., Skarke,C., Schmidt,H., Rohrbacher,M., Hofmann,U.,
Schwab,M. and Geisslinger,G. (2006) Evidence for
morphine-independent central nervous opioid effects after
administration of codeine: contribution of other codeine metabolites.
Clin. Pharm. Th., 79, 35–48.
4. Wilkinson,M.D., Dumontier,M., Aalbersberg,I.J.J., Appleton,G.,
Axton,M., Baak,A., Blomberg,N., Boiten,J.-W., da Silva Santos,L.B.,
Bourne,P.E. et al. (2016) The FAIR Guiding Principles for scientific
data management and stewardship. Scientific Data, 3, 160018.
5. Ioannidis,J.P.A. (2019) Reproducible pharmacokinetics. J.
Pharmacokinet. Phar., 46, 111–116.
6. Mould,D.R. and Upton,R.N. (2012) Basic concepts in population
modeling, simulation, and model-based drug development. CPT:
Pharmacometrics Syst. Pharmacol., 1, e6.
7. Mould,D.R. and Upton,R.N. (2013) Basic concepts in population
modeling, simulation, and model-based drug development-part 2:
introduction to pharmacokinetic modeling methods. CPT:
Pharmacometrics Syst. Pharmacol., 2, e38.
8. Upton,R.N. and Mould,D.R. (2014) Basic concepts in population
modeling, simulation, and model-based drug development: part
3-introduction to pharmacodynamic modeling methods. CPT:
Pharmacometrics Syst. Pharmacol., 3, e88.
9. König,M. and Grzegorzewski,J. (2020) matthiaskoenig/pkdb: release
notes for pkdb-v0.9.3.
10. Hastings,J., Owen,G., Dekker,A., Ennis,M., Kale,N.,
Muthukrishnan,V., Turner,S., Swainston,N., Mendes,P. and
Steinbeck,C. (2016) ChEBI in 2016: improved services and an
expanding collection of metabolites. Nucleic Acids Res., 44,
D1214–D1219.
11. Sioutos,N., de Coronado,S., Haber,M.W., Hartel,F.W., Shaiu,W.-L.
and Wright,L.W. (2007) NCI Thesaurus: a semantic model
integrating cancer-related clinical and molecular information. J.
Biomed. Inform., 40, 30–43.
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